Happy Valentine’s Day!
Have a look at two opportunities in research for our patients affected by addiction to opioids. The first is through the Northeast NIDA Node at Dartmouth.
I am writing on behalf of the Lead Investigator, David Fiellin, MD, Co-Lead Investigator, Paul Joudrey, MD, and the entire Lead Team of the CTN-0131: Office-based Methadone Versus Buprenorphine to Address Retention in Medication for Opioid Use Disorder Treatment – A Randomized Pragmatic Hybrid Effectiveness/Implementation Trial protocol.
We will conduct a randomized, pragmatic hybrid type 1 effectiveness/implementation multisite (6 practices) trial to determine whether office-based methadone with pharmacy administration and/or dispensing or buprenorphine (BUP) results in greater treatment retention in approximately 600 patients with opioid use disorder (OUD). As part of the trial, we will identify implementation barriers, facilitators and acceptability at the patient, provider, and health-systems level for office-based methadone with pharmacy administration and/or dispensing.
More information about the study can be found in the attached synopsis.
Please circulate this email to potential practices and encourage them to complete the attached site selection survey. If you are affiliated with the NIDA Clinical Trials Network (CTN), we would like the surveys collected and returned to the Lead team through your Node PI/NC to confirm their endorsement.
Please have the completed survey and any questions sent to Jessica McKenzie, email@example.com . The deadline for receiving surveys is Thursday April 6, 2023. Please be feel free to contact us with any questions you may have.
*We will be holding a webinar on February 15, 12:00-1:00, to provide an overview of the study and answer any questions. Please see the attached flyer for registration details.
Research Project Director
New England Consortium Node Coordinator
Department of Psychiatry
Temple Medical Building
40 Temple St, Suite 6C
New Haven, CT 06510
The second is through UVM.
The University of Vermont Center on Rural Addiction (UVM CORA) has been authorized to distribute five intranasal naloxone (IN) vending machines to qualifying health organizations in Vermont, New Hampshire, Maine, and Northern New York.
In our ongoing efforts to provide evidence-based harm reduction resources to rural communities, the overarching goal of this program is to increase access for emergency uses and for individuals who may not otherwise engage in services. The vending machines provided through this program will be placed in centralized locations in rural communities in Northern New England. The IN doses within these vending machines do not require health insurance or a prescription to obtain. Selected organizations will be tasked with the development and oversight of infrastructure and programmatic capacity at the vending site, including community engagement, data sharing, and overall machine and software maintenance.
To be eligible for this program, organizations must be non-profit, located in a HRSA-designated rural community, and licensed to conduct business within Vermont, New Hampshire, Maine, or Northern New York.
UVM CORA encourages applications from rural health organizations that promote the health and dignity of individuals and communities impacted by substance use and those that wish to incorporate this mission into their core activities. Applicants must demonstrate their understanding of harm reduction principles and practice. Both existing providers and new providers without a previous portfolio in harm reduction and/or the treatment of people with substance use disorders are eligible. However, organizations demonstrating prior expertise working with people with opioid use disorder or a formal partnership with an experienced agency will be prioritized.
In order to obtain a vending machine, UVM requires recipients to enter a subaward agreement with the university. A UVM financial analyst will need financial information from the recipient’s organization to conduct a risk assessment and determine if UVM can enter into a subaward agreement with the organization.
Applicants must agree to the following:
Designate a reliable contact person with decision making and signing authority who will serve as the subaward Principle Investigator.
Maintain consistent communication with UVM CORA throughout the application process.
Provide the requested financial information required to enter a subaward agreement with UVM.
Consistently stock the vending machine with IN (UVM CORA will fill the machine twice after placement).
Maintain the vending machine after its placement, including any necessary software updates and repairs.
Agree to data sharing as part of the quarterly reporting process to the UVM CORA funder (HRSA).
Application Deadline and Program Timeline
The application deadline is March 3, 2023 by 5:00 p.m. ET
Organizations will be notified in March on the next steps in the application and interview process.
More Information & Apply
Visit UVMCORA.org to learn more about who we are and what we do. You can also contact us directly at CORA@uvm.edu.
And don’t forget to register for our Annual Scientific Meeting to be held in Portland, Maine on April 28 and 29!